Skip to content
Open access

Cardiomyocyte-enriched OTUD5 alleviates pathological myocardial hypertrophy by deubiquitinating STAT3 and modulating the STAT3–PGC-1α axis

Oct 2026 · Experimental and Molecular Medicine · Vol 58, pp. 3579 - 3592 · 0 citations · 45 references
Medicine

Abstract

Pathological cardiac hypertrophy presents a important public health challenge, particularly in aging populations, highlighting the urgent need for novel therapeutic targets. This study investigates the role and molecular mechanisms of OTUD5 in pathological cardiac hypertrophy. OTUD5 expression is greatly increased in cardiomyocytes from hypertrophic hearts. Deleting cardiomyocyte-specific OTUD5 exacerbates myocardial hypertrophy induced by angiotensin II (Ang II) and transverse aortic constriction (TAC). By contrast, targeted overexpression of OTUD5 in cardiomyocytes alleviates Ang II-induced pathological hypertrophy. Mechanistically, we demonstrate that OTUD5 regulates STAT3 activity by removing the K63-linked ubiquitin chain at lysine 283 (K283) on STAT3 through its C224 residue. This process inhibits both phosphorylation and nuclear translocation of STAT3, effectively relieving its transcriptional repression of PGC1α and enhancing mitochondrial function within cardiomyocytes. Our research uncovers a new OTUD5–STAT3–PGC1α axis that modulates mitochondrial bioenergetics, suggesting it as a potential therapeutic target for pathological cardiac hypertrophy. Pathological cardiac hypertrophy, a major contributor to heart failure, poses important public health challenges. This study explores the role of OTUD5, a deubiquitinase, in regulating cardiac hypertrophy through a new mechanism. Researchers developed a cardiomyocyte-specific Otud5-knockout mouse model to investigate its function in pathological myocardial hypertrophy. They found that OTUD5 expression increased in hypertrophic cardiomyocytes, acting as a protective factor. OTUD5 deficiency exacerbated cardiac hypertrophy and dysfunction in mice, whereas its overexpression alleviated these conditions. OTUD5 achieves this by deubiquitinating STAT3 at the K283 site, inhibiting its activation and nuclear translocation, which in turn enhances PGC1α expression and mitochondrial function. These findings highlight the OTUD5–STAT3–PGC1α axis as a potential therapeutic target for heart failure, suggesting that future research can focus on developing OTUD5 modulators to improve cardiac health. "This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author."

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.